Previous 10 | Next 10 |
Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs Dosing Level Established For Advanced Clinical Trials SEATTLE, WA / A...
Aptevo Therapeutics (APVO): Q1 GAAP EPS of -$1.74 misses by $0.12.Revenue of $2.42M misses by $10.65M.Press Release For further details see: Aptevo Therapeutics EPS misses by $0.12, misses on revenue
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology ...
SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR TM and ADAPTIR-FLEX TM platform technologies, today announced that it will p...
Aptevo Therapeutics (APVO): FY GAAP EPS of -$5.23 misses by $0.66.Revenue of $4.31M beats by $0.63M.Press Release For further details see: Aptevo Therapeutics EPS misses by $0.66, beats on revenue
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Ag...
Today, we take our first look at a small developmental concern based out of Seattle called Aptevo. The stock was in the news of late last year, thanks to a buyout offer and some trial developments. A full analysis on Aptevo Therapeutics follows in the paragraphs below. ...
Stockholders Are Not Required to Take Any Action at this Time SEATTLE, WA / ACCESSWIRE / February 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ an...
Click here to read the previous top NASDAQ biotech stocks article. It’s been a stellar year for the NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ), which started at 3,763.05 points in January and reached a high of 4,811.03 points on December 15. While the inde...
Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer. Although early stage, this is a definite candidate for my watchlist. For further details see: Aptevo: Positive Early Stage Data Makes This Highly Interesting...
News, Short Squeeze, Breakout and More Instantly...
Aptevo Therapeutics Inc. Company Name:
APVO Stock Symbol:
NASDAQ Market:
Aptevo Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...
2024-07-18 06:16:00 ET 3 Tips for Using RSI When Investing in Penny Stocks Relative Strength Index (RSI) is a powerful tool for evaluating the momentum of stocks, and it can be particularly effective when investing in penny stocks . Penny stocks offer unique opportunities due to the...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...